YOLFTbeta
37

BioNote Inc.

377740 · KO · Healthcare / Medical Devices

4,520.00KRW-90.00 (-1.95%)

Price History

Full chart

Market Stats

Previous Close4,610.00
Open4,625.00
Day Range4,440.00 – 4,625.00
52-Week Range4,050.00 – 5,999.55
Volume86.91K
Market Cap474.29B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield4.85%
Beta0.63
50-Day Avg4,726.20
200-Day Avg5,065.33

About

BioNote, Inc., manufactures and sells in-vitro diagnostic animal medicines in South Korea. It offers animal diagnostics products, such as fluorescence immunoassay, molecular diagnostics, clinical biochemistry, rapid immunoassay, and enzyme-linked immunosorbent assay products. The company also provides bio-content products, including rapid immunoassay for humans, human intermediate goods, and bio-contents reagents. In addition, it engages in the production and sell of medical devices. BioNote, Inc. was founded in 2003 and is headquartered in Hwaseong-si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. ByungKi Cho
  • Employees299
  • Headquarters22, Samsung 1-ro 4-gil, Hwaseong-si, South Korea, Korea
  • Websitehttps://www.bionote.co.kr

Leadership

  • Mr. ByungKi ChoCEO & Representative Director · b. 1967
  • Mr. GukMyeong LeeMD & CFO · b. 1972
  • Ms. GeumYoung OhSenior Accounting Manager
  • Mr. JeongHwan LimExecutive Director and GM of Management Headquarters & Legal Department · b. 1971
  • Mr. JeongHo KimExecutive Director · b. 1976
  • Ms. Hyeim ChoHead of Marketing Strategy Office & Executive Director · b. 1987
  • Mr. JuHwan SungMD & GM of Operations Support Office · b. 1973
  • Mr. IlJung KimExecutive Director · b. 1976
  • Mr. MyoungKyu ChungHead of Diagnostic Reagent Production Division · b. 1983
  • Mr. SangYoung JeongMD & Head of New Drug Development Business Division · b. 1977

Financials

Income Statement

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue40.05B631.50B622.36B479.66B90.08B102.78B118.32B
Growth (%)-+1476.89%-1.45%-22.93%-81.22%+14.10%+15.12%
Cost of Revenue21.33B51.92B110.29B138.93B101.65B51.54B52.56B
Gross Profit18.72B579.58B512.06B340.73B-11.57B51.24B65.77B
Gross Margin46.75%91.78%82.28%71.04%-12.84%49.85%55.58%
Operating Expense8.79B21.55B43.32B45.32B35.47B39.02B48.96B
Operating Income9.93B558.03B468.75B295.41B-47.04B12.22B16.81B
Operating Margin24.79%88.37%75.32%61.59%-52.22%11.89%14.21%
EBITDA27.10B697.26B869.82B421.31B-100.68B81.75B-78.05B
EBITDA Margin67.66%110.41%139.76%87.84%-111.77%79.54%-65.97%
Net Income20.61B528.23B676.60B307.80B-20.50B55.26B-87.50B
Net Income Margin51.47%83.65%108.72%64.17%-22.75%53.77%-73.95%
R&D3.63B7.61B11.30B16.14B13.40B13.58B16.84B
R&D as % of Total Revenue9.06%1.21%1.82%3.36%14.88%13.21%14.23%
Interest Expense468.26M172.63M44.25M84.44M602.82M233.55M287.12M
Interest Expense % of Total Revenue1.17%0.03%0.01%0.02%0.67%0.23%0.24%

Balance Sheet

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets130.83B853.44B1.49T1.76T1.59T1.70T1.56T
Total Liabilities20.25B214.74B216.36B156.85B36.27B61.38B44.65B
Total Equity110.58B638.70B1.27T1.60T1.56T1.64T1.51T
Cash6.58B123.08B418.61B681.07B147.40B107.34B17.87B
Net Debt5.42B------

Cash Flow

Currency: KRW2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow9.85B239.93B537.39B249.10B-4.19B57.92B14.38B
Capital Expenditure1.53B26.72B51.54B42.48B4.54B10.48B8.27B
Free Cash Flow8.32B213.20B485.85B206.62B-8.74B47.43B6.11B
Dividends Paid--49.96B49.96B49.92B20.41B20.27B
FCF to OCF84.49%88.86%90.41%82.95%208.31%81.90%42.50%
Dividend Paid to FCF--10.28%24.18%-571.44%43.03%331.70%

Earnings

Report DateDec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023May 16, 2024Aug 14, 2024Nov 14, 2024Feb 25, 2025May 15, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------7.31-3.03-------
EPS Actual-1366.71-223.38-546.48605.30-36.82165.7266.00201.00109.7639.74833.87177.25-1931.59410.1890.21
Surprise------1002.87%6733.66%-------
Timing-----Pre-marketPre-market-Pre-marketPre-market-----

Key Statistics & Ratios

Market Cap474.29B
Enterprise Value103.68B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.75
Price / Book0.30
Revenue (TTM)126.41B
Gross Profit (TTM)71.39B
EBITDA30.52B
Profit Margin-99.43%
Operating Margin23.27%
Return on Equity-7.79%
Return on Assets0.77%
Shares Outstanding100.91M
Shares Float13.19M
Beta0.63
Dividend Yield4.85%
Dividend Rate228.00
Payout Ratio17.23%

Dividends

20261×
228.00Mar 30, 2026
20251×
200.00Mar 28, 2025
20241×
200.00Mar 28, 2024
20221×
490.00Dec 28, 2022